Press "Enter" to skip to content

U.S. drug developer Capricor places Duchenne drug trial on hold

The review follows a severe allergic reaction during infusion of the drug, the company said in a filing. The patient responded well to medical treatment and is currently asymptomatic.

Original source:

Also Read:   Zydus delivers first batch of antibody test kits to ICMR